Thor Medical ASAFRA:8NN +0.67%26 Quick Ratio is 4.50 as of Dec. 2025, which is 1% above its 10-year median of 4.45. GuruFocus rates FRA:8NN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Thor Medical ASA ranks better than 56.16% on this metric.
Thor Medical ASA has a quick ratio of 4.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Thor Medical ASA's Quick Ratio or its related term are showing as below:
FRA:8NN'
s Quick Ratio Range Over the Past 10 Years
Min: 1.92 Med: 4.45 Max: 10.91
Current: 4.5
During the past 13 years, Thor Medical ASA's highest Quick Ratio was 10.91. The lowest was 1.92. And the median was 4.45.
FRA:8NN's Quick Ratio is ranked better than 56.16% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:8NN: 4.50
Thor Medical ASA (FRA:8NN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Thor Medical ASA Quick Ratio Related Terms
Thor Medical ASA Quick Ratio Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8NN vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Thor Medical ASA's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Thor Medical ASA's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thor Medical ASA (FRA:8NN) has a Quick Ratio of 4.50 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Thor Medical ASA and its competitors. This is near median its historical median of 4.45. Over the past decade, Thor Medical ASA's Quick Ratio has ranged from 1.92 to 10.91. According to the industry distribution chart, Thor Medical ASA ranks #619 out of 1412 companies in the Biotechnology industry, placing it in the top 43.8%.
Is Thor Medical ASA's Quick Ratio too high?
Thor Medical ASA's current Quick Ratio of 4.50 is near median its 10-year median of 4.45. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 10.91. The Biotechnology industry median Quick Ratio is 3.60. Thor Medical ASA's value of 4.50 is 25% above this industry median. Based on the distribution chart, Thor Medical ASA ranks #619 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #619 out of 1412 companies for Quick Ratio. This puts Thor Medical ASA in the upper half of its industry. The industry median Quick Ratio is 3.60. Thor Medical ASA's value of 4.50 is 25% above this benchmark. Historically, Thor Medical ASA's own Quick Ratio has ranged from 1.92 to 10.91 over the past decade. While the company's 10-year median is 4.45 vs. the industry median of 3.60, Thor Medical ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thor Medical ASA's current Quick Ratio of 4.50 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Thor Medical ASA and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thor Medical ASA's current Quick Ratio is 4.50, which is near median its own 10-year median of 4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Quick Ratio of 4.50. The current Quick Ratio is 4.50, which is near median its 10-year median of 4.45 and 25% above the Biotechnology industry median of 3.60. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Quick Ratio is 4.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score
Get the complete analysis for FRA:8NN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
